Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. While there is strong volume growth and positive trends in market expansion, the delay in profitability targets and ASP challenges weigh negatively. The Q&A reveals management's cautious stance on profitability timelines and ASP, which adds uncertainty. However, the company's strategic investments and potential ASP improvements, alongside strong relationships with ACR, provide a balance. Without market cap data, a neutral prediction (-2% to 2%) is reasonable, reflecting both positive growth aspects and financial uncertainties.
Key Financial Performance
Revenue Full year 2025 revenue reached a record $66.6 million, a near 20% increase over 2024. This growth was driven by an 11% increase in testing volume and a 7% increase in trailing 12-month ASP.
Testing Volume In 2025, testing volume grew by over 11%, with a reset in the volume run rate from roughly 30,000 tests in Q1 to 35,000+ in subsequent quarters. Q4 2025 marked the highest Q4 testing volume in Exagen's history, bucking typical second-half seasonality.
Average Selling Price (ASP) Trailing 12-month ASP at the end of 2025 was approximately $441, up about 7% from $411 at the start of the year. This was driven by new product enhancements, improved revenue cycle management, and payer advocacy.
Gross Margin Gross margin for 2025 was just over 58%, compared to about 60% in 2024. The decline was attributed to ASP pressure in the second half of the year, though cost management efforts in the lab and supply chain provided some offset.
Operating Expenses Full year 2025 operating expenses were $53 million, up about 13% compared to 2024. This increase was primarily due to investments in commercial talent and territory expansion, as well as R&D for new product launches.
Adjusted EBITDA Loss Adjusted EBITDA loss for 2025 was $9.8 million, a moderate improvement over 2024. This reflects disciplined expense management and revenue growth.
Cash and Cash Equivalents At the end of 2025, cash, cash equivalents, and restricted cash totaled just over $32 million. This was supported by $26 million in net proceeds from debt refinancing, follow-on offering, and ATM utilization.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Launch of new biomarkers: Three sets of innovative markers were launched into the clinic within an 18-month period, including T-cell and RA33 biomarkers, which contributed significantly to ASP growth.
Pipeline development: Five promising assets are in development, with plans to launch one product each year. Focus areas include solutions for myositis, lupus nephritis, and disease activity measures for SLE and RA.
Sales force expansion: Sales territories expanded from 40 to 45, with new hires expected to improve productivity over time.
International presence: Recent manuscript submissions and participation in international conferences, such as the International Autoimmune Conference in Prague, highlight efforts to expand presence in the autoimmune field.
Revenue cycle management: Upgraded customer service, established prior authorization processes, and improved reimbursement through effective appeals and payer advocacy.
Sales team restructuring: Reduced the sales team by one-third initially, upgraded talent, and cultivated a culture conducive to innovation and integrity.
Cost management: Streamlined workflows in the lab and reduced supply chain costs, resulting in COGS per test tracking below internal targets.
Focus on profitable growth: Transitioned away from unprofitable customers and processes, and prioritized R&D efforts with clear commercial viability.
Advocacy and partnerships: Secured advocacy from the American College of Rheumatology and engaged with medical directors to drive medical policy progress.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Cycle Management: Challenges in improving reimbursement processes, including upgrading customer service, establishing prior authorization processes, and managing appeals effectively. These efforts are critical but resource-intensive.
Sales Force Restructuring: Reduction of the sales team by one-third and managing out underperforming employees posed risks to operational continuity and morale during the transition.
R&D Streamlining: Discontinuation of lower-potential initiatives and walking away from programs with significant sunk costs created challenges in reallocating resources and maintaining focus on high-priority projects.
Transition from Unprofitable Customers: Transitioning away from unprofitable customers and processes involved risks of unforeseen second and third-order impacts, potentially affecting revenue stability.
ASP (Average Selling Price) Expansion: Pressure on ASP in the second half of 2025, with challenges in maintaining consistent growth despite strategic initiatives.
Gross Margin Management: Gross margin declined from 60% in 2024 to 58% in 2025, reflecting ASP pressures and the need for further cost optimization in supply chain and lab workflows.
Cash Flow Management: High use of cash in the first half of the year due to holding claims, creating potential liquidity challenges.
Regulatory and Market Access: Uncertainty in timing for local coverage determination and payer advocacy progress, which are critical for expanding market access and ASP.
Product Development and Launch: Challenges in formalizing a product cadence and ensuring successful commercialization of new products, such as solutions for myositis and lupus nephritis.
International and Domestic Expansion: Efforts to expand presence in the autoimmune field require significant investment and carry risks of overextension.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Exagen Inc. is guiding revenue expectations for the full year 2026 to be between $70 million to $73 million, reflecting continued progress with both volume and ASP contributing to growth.
Volume Growth: The company expects high single-digit volume growth for the full year 2026, driven by an upgraded and expanding sales force and strong momentum from 2025.
ASP Growth: Low single-digit ASP growth is anticipated from Q4 2025 levels, with trailing 12-month ASP expected to continue improving due to strategic initiatives such as revenue cycle optimizations and market access efforts.
Pipeline Development: Exagen plans to launch one new product each year, with five promising assets currently in development. The company is focusing on solutions for myositis, lupus nephritis, and disease activity measures for SLE and RA.
Profitability Goals: The company aims to achieve breakeven adjusted EBITDA and begin generating cash at an $80 million revenue run rate, supported by ASP in the high $400 to $500 range and gross margins in the low to mid-60s.
Market Access and Advocacy: Exagen is engaging with payers and medical directors to drive medical policy progress and improve patient access to its AVISE franchise. The company has secured advocacy from the American College of Rheumatology and is pursuing local coverage determinations.
International and Domestic Expansion: The company is advancing its presence in the autoimmune field with recent manuscript submissions and plans to present abstracts at international conferences, including the International Autoimmune Conference in Prague and ACR later in the year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why is the company making investments now despite delaying profitability targets?
A:The company has increased its breakeven revenue level to $80 million due to investments in the commercial organization and R&D. They have upgraded their team, expanded commercially, and returned to reinvestment in the pipeline. The CFO highlighted that the gross margin profile is encouraging, with a COGS profile in the high $400s to $500 range, aiming for a mid-60% gross margin.
Q:What is the commercialization target for the myositis offering?
A:The company is developing a product for myositis, with internal feasibility studies completed and validation underway. The offering is expected to be ready for the clinic by 2027.
Q:What is the guidance for ASP (average selling price) and its implications for Q4 2026?
A:The company has not disclosed the expected trailing 12-month ASP but expects stabilization in the first half of the year and incremental gains in the second half. The CEO views the Northwell situation as a one-time event and does not anticipate further degradation.
Q:What is the impact of the Northwell situation on volume and revenue?
A:The Northwell situation accounted for 2% of overall volume and a $25 impact on ASP. The company expects the trailing 12-month ASP to fully reflect this impact by the end of Q2. Despite this, the company achieved 22% volume growth in Q4 compared to the previous year.
Q:How is the company leveraging ACR (American College of Rheumatology) support?
A:The company has developed strong relationships with ACR members and established a communication path for rheumatologists to advocate for the AVISE platform. ACR is now advocating to medical directors of commercial insurers, which is expected to positively impact the business over the next 1-2 years.
Q:What is the timeline for achieving EBITDA and cash flow positivity?
A:The company has guided to $70-$73 million in revenue for the year, with a breakeven target of $80 million. Achieving EBITDA and cash flow positivity is expected by 2027, though earlier achievement is possible with higher ASP or volume growth.
Q:What is the current ASP and its trajectory?
A:The in-period ASP dropped to around $430 in Q3 and Q4, with expectations to grow from there. The company aims for low single-digit ASP growth relative to the second half ASP level.
Q:What is the impact of new biomarkers on ASP and gross margin?
A:The addition of 7 new biomarkers increased COGS per test but did not significantly impact gross margin due to better-than-expected COGS performance. The ASP for new biomarkers is approaching $80, with a target of $90 by 2027.
Q:What is the status of the local coverage determination (LCD) for rheumatologic disease?
A:The LCD is in progress with MolDX and is expected to cover testing in rheumatologic conditions. The company maintains its Medicare reimbursement and expects the LCD to help with Medicare Advantage and commercial insurers.
Q:What are the key drivers of volume growth?
A:Volume growth is driven by an increase in ordering physicians (from 2,370 in 2024 to 2,690 in 2025) and greater penetration within accounts. The company achieved 137,000 AVISE CTD tests in 2025, with 22% volume growth in Q4 compared to the previous year.
Q:What is the progress and impact of the sales force expansion?
A:The sales force expanded from 40 to 45 territories, with new hires expected to become proficient by spring to summer. The company plans further expansion based on the success of current additions.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the expected trailing 12-month ASP, the exact timing of EBITDA and cash flow positivity, and the calculated Q4 ASP. They also did not provide a clear timeline for the LCD draft release or specific data on the impact of new biomarkers on ASP.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACR engagement
ACR lot
ASP start
ASP term
ASP way
Autoimmune Conference
Blues plan
CEO today
Conference Prague
Instructions conference
International Autoimmune
Jacobsen Vice
None action
Prague abstract
President Investor
RD effort
Today
advocacy
answer
cadence
channel
clarity
consequence
culture
diagnosis
diagnostics space
director
discipline
foundation
future
health care
lot work
manuscript
meeting
oncology
problem
solution
suspicion
volume sale
XGN Transcript
Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript
Unknown3-10
The earnings call presents a mixed outlook. While there is strong volume growth and positive trends in market expansion, the delay in profitability targets and ASP challenges weigh negatively. The Q&A reveals management's cautious stance on profitability timelines and ASP, which adds uncertainty. However, the company's strategic investments and potential ASP improvements, alongside strong relationships with ACR, provide a balance. Without market cap data, a neutral prediction (-2% to 2%) is reasonable, reflecting both positive growth aspects and financial uncertainties.
Exagen Inc. (XGN) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call summary suggests mixed signals: positive revenue growth and ASP expansion are countered by challenges in achieving ASP targets and addressing payment denials. The Q&A section reveals management's unclear responses on key metrics, raising concerns. However, the strategic plan for 2025 shows optimism with new biomarker launches and potential pharma partnerships. Overall, the sentiment is balanced, leading to a neutral prediction for stock price movement over the next two weeks.
Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript
Positive7-29
The earnings call reveals strong financial performance with improved gross margins and sustainable volume growth. Management is confident in achieving the ASP increase, and the strategic expansion of territories and pipeline developments are promising. Despite some increase in operating expenses and net loss, the company is on track for positive adjusted EBITDA and free cash flow. The Q&A section supports the positive outlook, highlighting market potential and strategic initiatives. While management avoided specific guidance on volume, the overall sentiment remains positive with expectations of continued growth.
Exagen Inc. (NASDAQ:XGN) Q1 2025 Earnings Call Transcript
Unknown5-11
The earnings call presents mixed signals. While revenue increased by 8% and there's a positive outlook for new biomarker launches, gross margin slightly declined and net loss widened. The new credit facility and debt refinancing are positive, enhancing financial flexibility. However, management's vague guidance, especially regarding volume and margins, introduces uncertainty. The Q&A reveals cautious optimism but lacks clarity on future growth. Given these factors, the stock price is likely to remain stable, leading to a neutral prediction.
XGN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
